Cargando…
Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?
IgA nephropathy (IgAN) is characterized by a variable clinical course and multifaceted pathophysiology. There is substantial evidence to suggest that complement activation plays a pivotal role in the pathogenesis of the disease. Therefore, complement inhibition using the humanized anti-C5 monoclonal...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581393/ https://www.ncbi.nlm.nih.gov/pubmed/26413271 http://dx.doi.org/10.1093/ckj/sfv076 |